Metraipolis › archive › dc_4de36f41508d

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis — Europe PMC PMID:42637879

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42637879
DOI
10.1038/s41375-[numero omesso]-9
License (as archived)
solo-consultazione
Archived
2026-10-31T10:35:46.518Z
SHA-256 of the archived text
217c252f37cff4802c3bc1ca1cbba5cf16ca96de5923bb950d6032081074b0ac
Stable URL of this page
https://metraipolis.com/documento/dc_4de36f41508d

How to cite

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis — Europe PMC PMID:42637879 — Europe PMC (en), https://europepmc.org/article/MED/42637879 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4de36f41508d (Metraipolis archive dc_4de36f41508d, sha256 217c252f37cff4802c3bc1ca1cbba5cf16ca96de5923bb950d6032081074b0ac)
BibTeX
@misc{dc4de36f41508d,
  title = {Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis — Europe PMC PMID:42637879},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42637879},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4de36f41508d; sha256 217c252f37cff4802c3bc1ca1cbba5cf16ca96de5923bb950d6032081074b0ac},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42637879. Agents can read the archived copy with the MCP tool read_document.